News
Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the ...
The Rahway, N.J., drug maker said Friday that its treatment, Keytruda, has been approved for adult patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express ...
Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...
However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...
Merck KGaA has shed more light on the failure of its lupus drug in one cohort of patients, while pointing to secondary ...
Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...
Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair ...
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...
Merck is establishing a program of clinical trials for V181, including conducting trials globally, in places where dengue is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback